Uterine fibroids (leiomyomas) are the most common benign tumors in women, with a lifetime incidence up to 70%. While hysterectomy has long been the definitive cure, medical therapies are increasingly helping women avoid surgery.

Understanding Fibroid-Related Symptoms

• Heavy Menstrual Bleeding: Can lead to anemia and fatigue.

• Bulk Symptoms: Pelvic pressure, urinary frequency, and constipation.

• Reproductive Impact: Subfertility or pregnancy complications.

Why Medical Therapy Matters

• Uterine Preservation: Maintains fertility and hormonal function.

• Quality of Life: Reduces bleeding and bulk symptoms without hospitalization.

Mifepristone (Mifestone-25®) in Focus

• Mechanism: Acts as a selective progesterone receptor modulator, inducing fibroid shrinkage and decreasing extracellular matrix.

• Clinical Data: Up to 98% of patients report significant volume reduction; hemoglobin levels improve by ~2.8 g/dL on average.

• Dosing: 25 mg once daily for up to 12 months, monitored with periodic ultrasounds and labs.

Integrating Therapy into Practice

1. Baseline Workup: Ultrasound sizing, CBC, and liver panel.

2. Monitoring: Ultrasound every 3–6 months; adjust duration based on response.

3. Adjunctive Support: Iron supplementation for heavy bleeding.

Patient Story (Case Study)

“After three months on Mifestone-25®, my periods went from 8 days of heavy bleeding to 3 days of light spotting—and my fibroid shrank by over 40%!”

Conclusion & Call to Action
Medical management with Mifestone-25® offers a non-surgical pathway for fibroid relief. Consult your gynecologist to see if SPRM therapy fits your treatment plan.